 | • レポートコード：MRC23Q35994 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の家族性カイロミクロン血症症候群治療薬市場について調査・分析し、世界の家族性カイロミクロン血症症候群治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（健康補助食品家族性カイロミクロン血症治療剤、遺伝子治療剤家族性カイロミクロン血症治療剤）、用途別セグメント分析（病院薬局、小売店薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Akcea Therapeutics、Ionis Pharmaceuticals、uniQure N.V.、McKinsey & Company、Amgen Inc.、F. Hoffmann-La Roche Ltd、Pfizer Inc.、Novartis AG、Janssen Global Services, LLC、AMAG Pharmaceuticals、Teva Pharmaceutical Industries Ltd、Rockwell Medical、Vifor Pharma Management Ltd.、Akebia Therapeutics.などが含まれています。 世界の家族性カイロミクロン血症症候群治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、家族性カイロミクロン血症症候群治療薬市場規模を推定する際に考慮しました。本レポートは、家族性カイロミクロン血症症候群治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、家族性カイロミクロン血症症候群治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・家族性カイロミクロン血症症候群治療薬市場の概要 - 家族性カイロミクロン血症症候群治療薬のタイプ別セグメント - 世界の家族性カイロミクロン血症症候群治療薬市場規模：タイプ別分析（健康補助食品家族性カイロミクロン血症治療剤、遺伝子治療剤家族性カイロミクロン血症治療剤） - 家族性カイロミクロン血症症候群治療薬の用途別セグメント - 世界の家族性カイロミクロン血症症候群治療薬市場規模：用途別分析（病院薬局、小売店薬局、その他） - 世界の家族性カイロミクロン血症症候群治療薬市場規模予測（2018年-2029年） ・家族性カイロミクロン血症症候群治療薬市場の成長トレンド - 家族性カイロミクロン血症症候群治療薬の地域別市場規模（2018年-2029年） - 家族性カイロミクロン血症症候群治療薬市場ダイナミクス - 家族性カイロミクロン血症症候群治療薬の業界動向 - 家族性カイロミクロン血症症候群治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：健康補助食品家族性カイロミクロン血症治療剤、遺伝子治療剤家族性カイロミクロン血症治療剤 - 世界の家族性カイロミクロン血症症候群治療薬のタイプ別市場規模（2018年-2023年） - 世界の家族性カイロミクロン血症症候群治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、小売店薬局、その他 - 世界の家族性カイロミクロン血症症候群治療薬の用途別市場規模（2018年-2023年） - 世界の家族性カイロミクロン血症症候群治療薬の用途別市場規模（2024年-2029年） ・家族性カイロミクロン血症症候群治療薬の地域別市場規模 - 北米の家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - アメリカの家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - ヨーロッパの家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - アジア太平洋の家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - 中国の家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - 日本の家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - 韓国の家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - インドの家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - オーストラリアの家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - 中南米の家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） - 中東・アフリカの家族性カイロミクロン血症症候群治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Akcea Therapeutics、Ionis Pharmaceuticals、uniQure N.V.、McKinsey & Company、Amgen Inc.、F. Hoffmann-La Roche Ltd、Pfizer Inc.、Novartis AG、Janssen Global Services, LLC、AMAG Pharmaceuticals、Teva Pharmaceutical Industries Ltd、Rockwell Medical、Vifor Pharma Management Ltd.、Akebia Therapeutics. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Familial Chylomicronemia Syndrome Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Familial Chylomicronemia Syndrome Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Familial Chylomicronemia Syndrome Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Familial Chylomicronemia Syndrome Therapeutics in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Familial Chylomicronemia Syndrome Therapeutics include Akcea Therapeutics, Ionis Pharmaceuticals, uniQure N.V., McKinsey & Company, Amgen Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG and Janssen Global Services, LLC, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Familial Chylomicronemia Syndrome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Familial Chylomicronemia Syndrome Therapeutics.
The Familial Chylomicronemia Syndrome Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Familial Chylomicronemia Syndrome Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Familial Chylomicronemia Syndrome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Akcea Therapeutics
Ionis Pharmaceuticals
uniQure N.V.
McKinsey & Company
Amgen Inc.
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Novartis AG
Janssen Global Services, LLC
AMAG Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Rockwell Medical
Vifor Pharma Management Ltd.
Akebia Therapeutics.
Segment by Type
Dietary Supplements Familial Chylomicronemia Syndrome Therapeutics
Gene Therapy Familial Chylomicronemia Syndrome Therapeutics
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Familial Chylomicronemia Syndrome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Familial Chylomicronemia Syndrome Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Dietary Supplements Familial Chylomicronemia Syndrome Therapeutics
1.2.3 Gene Therapy Familial Chylomicronemia Syndrome Therapeutics
1.3 Market by Application
1.3.1 Global Familial Chylomicronemia Syndrome Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Familial Chylomicronemia Syndrome Therapeutics Market Perspective (2018-2029)
2.2 Familial Chylomicronemia Syndrome Therapeutics Growth Trends by Region
2.2.1 Global Familial Chylomicronemia Syndrome Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Familial Chylomicronemia Syndrome Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Familial Chylomicronemia Syndrome Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Familial Chylomicronemia Syndrome Therapeutics Market Dynamics
2.3.1 Familial Chylomicronemia Syndrome Therapeutics Industry Trends
2.3.2 Familial Chylomicronemia Syndrome Therapeutics Market Drivers
2.3.3 Familial Chylomicronemia Syndrome Therapeutics Market Challenges
2.3.4 Familial Chylomicronemia Syndrome Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Familial Chylomicronemia Syndrome Therapeutics Players by Revenue
3.1.1 Global Top Familial Chylomicronemia Syndrome Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Familial Chylomicronemia Syndrome Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Familial Chylomicronemia Syndrome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Familial Chylomicronemia Syndrome Therapeutics Revenue
3.4 Global Familial Chylomicronemia Syndrome Therapeutics Market Concentration Ratio
3.4.1 Global Familial Chylomicronemia Syndrome Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Chylomicronemia Syndrome Therapeutics Revenue in 2022
3.5 Familial Chylomicronemia Syndrome Therapeutics Key Players Head office and Area Served
3.6 Key Players Familial Chylomicronemia Syndrome Therapeutics Product Solution and Service
3.7 Date of Enter into Familial Chylomicronemia Syndrome Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Chylomicronemia Syndrome Therapeutics Breakdown Data by Type
4.1 Global Familial Chylomicronemia Syndrome Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Familial Chylomicronemia Syndrome Therapeutics Forecasted Market Size by Type (2024-2029)
5 Familial Chylomicronemia Syndrome Therapeutics Breakdown Data by Application
5.1 Global Familial Chylomicronemia Syndrome Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Familial Chylomicronemia Syndrome Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Familial Chylomicronemia Syndrome Therapeutics Market Size (2018-2029)
6.2 North America Familial Chylomicronemia Syndrome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2018-2023)
6.4 North America Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Familial Chylomicronemia Syndrome Therapeutics Market Size (2018-2029)
7.2 Europe Familial Chylomicronemia Syndrome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2018-2023)
7.4 Europe Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Familial Chylomicronemia Syndrome Therapeutics Market Size (2018-2029)
9.2 Latin America Familial Chylomicronemia Syndrome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Akcea Therapeutics
11.1.1 Akcea Therapeutics Company Detail
11.1.2 Akcea Therapeutics Business Overview
11.1.3 Akcea Therapeutics Familial Chylomicronemia Syndrome Therapeutics Introduction
11.1.4 Akcea Therapeutics Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.1.5 Akcea Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Detail
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Familial Chylomicronemia Syndrome Therapeutics Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 uniQure N.V.
11.3.1 uniQure N.V. Company Detail
11.3.2 uniQure N.V. Business Overview
11.3.3 uniQure N.V. Familial Chylomicronemia Syndrome Therapeutics Introduction
11.3.4 uniQure N.V. Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.3.5 uniQure N.V. Recent Development
11.4 McKinsey & Company
11.4.1 McKinsey & Company Company Detail
11.4.2 McKinsey & Company Business Overview
11.4.3 McKinsey & Company Familial Chylomicronemia Syndrome Therapeutics Introduction
11.4.4 McKinsey & Company Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.4.5 McKinsey & Company Recent Development
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Detail
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Familial Chylomicronemia Syndrome Therapeutics Introduction
11.5.4 Amgen Inc. Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.5.5 Amgen Inc. Recent Development
11.6 F. Hoffmann-La Roche Ltd
11.6.1 F. Hoffmann-La Roche Ltd Company Detail
11.6.2 F. Hoffmann-La Roche Ltd Business Overview
11.6.3 F. Hoffmann-La Roche Ltd Familial Chylomicronemia Syndrome Therapeutics Introduction
11.6.4 F. Hoffmann-La Roche Ltd Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.6.5 F. Hoffmann-La Roche Ltd Recent Development
11.7 Pfizer Inc.
11.7.1 Pfizer Inc. Company Detail
11.7.2 Pfizer Inc. Business Overview
11.7.3 Pfizer Inc. Familial Chylomicronemia Syndrome Therapeutics Introduction
11.7.4 Pfizer Inc. Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.7.5 Pfizer Inc. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Familial Chylomicronemia Syndrome Therapeutics Introduction
11.8.4 Novartis AG Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.8.5 Novartis AG Recent Development
11.9 Janssen Global Services, LLC
11.9.1 Janssen Global Services, LLC Company Detail
11.9.2 Janssen Global Services, LLC Business Overview
11.9.3 Janssen Global Services, LLC Familial Chylomicronemia Syndrome Therapeutics Introduction
11.9.4 Janssen Global Services, LLC Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.9.5 Janssen Global Services, LLC Recent Development
11.10 AMAG Pharmaceuticals
11.10.1 AMAG Pharmaceuticals Company Detail
11.10.2 AMAG Pharmaceuticals Business Overview
11.10.3 AMAG Pharmaceuticals Familial Chylomicronemia Syndrome Therapeutics Introduction
11.10.4 AMAG Pharmaceuticals Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.10.5 AMAG Pharmaceuticals Recent Development
11.11 Teva Pharmaceutical Industries Ltd
11.11.1 Teva Pharmaceutical Industries Ltd Company Detail
11.11.2 Teva Pharmaceutical Industries Ltd Business Overview
11.11.3 Teva Pharmaceutical Industries Ltd Familial Chylomicronemia Syndrome Therapeutics Introduction
11.11.4 Teva Pharmaceutical Industries Ltd Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.11.5 Teva Pharmaceutical Industries Ltd Recent Development
11.12 Rockwell Medical
11.12.1 Rockwell Medical Company Detail
11.12.2 Rockwell Medical Business Overview
11.12.3 Rockwell Medical Familial Chylomicronemia Syndrome Therapeutics Introduction
11.12.4 Rockwell Medical Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.12.5 Rockwell Medical Recent Development
11.13 Vifor Pharma Management Ltd.
11.13.1 Vifor Pharma Management Ltd. Company Detail
11.13.2 Vifor Pharma Management Ltd. Business Overview
11.13.3 Vifor Pharma Management Ltd. Familial Chylomicronemia Syndrome Therapeutics Introduction
11.13.4 Vifor Pharma Management Ltd. Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.13.5 Vifor Pharma Management Ltd. Recent Development
11.14 Akebia Therapeutics.
11.14.1 Akebia Therapeutics. Company Detail
11.14.2 Akebia Therapeutics. Business Overview
11.14.3 Akebia Therapeutics. Familial Chylomicronemia Syndrome Therapeutics Introduction
11.14.4 Akebia Therapeutics. Revenue in Familial Chylomicronemia Syndrome Therapeutics Business (2018-2023)
11.14.5 Akebia Therapeutics. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details